Certara's Pivot: Divestiture, RIF, and the AI Inflection

A 52% rally rides a strategic swirl — new CCO, NVIDIA partnership, and a 'stranded costs' hangover — while the numbers still lag the ambition.

CERT · Earnings Call · 2026-08-04

A Company in Motion: Reshaping Around Software and AI

Certara's Q2 2026 call was less about the quarter's modest 1% revenue growth than about the pace of change inside the company. The stock has rallied 52% over the past 90 days even as management trimmed full-year margin guidance — a recomposition story, not a demand surge. CEO Jon Resnick's framing was unambiguous: “We are transforming Certara into a company we believe is capable of delivering sustainable double-digit growth. We still have work to do, but we are on the right path.” — Jon Resnick, Chief Executive Officer · 2026-08-04 The transformation rests on three pillars, all fresh since the start of 2026: the carve-out of the regulatory/medical writing business (closed May 8), a ~5% reduction in force, and the appointment of a new Chief Commercial Officer. The stranded costs from the divestiture are the most direct drag — “A portion of that shared infrastructure remains with us, while the associated revenue does not.” — Faiz Mohammed, Interim Chief Financial Officer · 2026-08-04 The RIF, executed in early Q3, offsets "a meaningful portion" of that impact and delivers ~$13M of run-rate savings. The strategic goal is clear: rebalance toward software, which now accounts for 53% of revenue versus 40% two years ago.

Software Leads, Services Lags — the Execution Gap

The reported economics remain in the trough. Q2 revenue was $93.3M (+1%), with software +4% and services -3%. On a continuing-ops basis revenue hit $107M, but operating income swung to a -$8M loss. The software-services split is the core tension — software bookings rose 9% (trailing 12-month +8%) while services posted a book-to-bill of just 1.07 and bookings fell 6%. Resnick frames the divergence as a deliberate repositioning: “It's been a focus on getting our specialists and our experts back out into market... That is early change days, but is yielding positive indicators.” — Jon Resnick, Chief Executive Officer · 2026-08-04 Pipeline grew 27% year-on-year, and leadership insists the inflection is a matter of execution rather than macro:

We're doing the things that we need to do in terms of setting the portfolio for long-term growth, making the investments, changing the P&L models and the operating models, changing the go-to-market incentives and the go-to-market model.
Jon Resnick, Chief Executive Officer · 2026-08-04

On NRR, management was reassuring — "no particular issue with NRR; absolute renewal rates of the organization were up in the quarter." The software engine is being nudged not only by renewals but by the desktop-to-cloud shift (Phoenix now has 30 cloud implementations this year) and by AI-augmented products. AI agents number nearly 600 in CoAuthor, driving a 40% productivity gain in drafting quality-control documents.

Regulatory Tailwinds and the NVIDIA Bet

The external environment is cooperating: the FDA issued guidance backing quantitative systems pharmacology for first-in-human dosing, and in July ICH M15 took effect at EMA — a genuinely new keyword for Certara this quarter, giving the US and Europe a shared standard for model-informed drug development. Resnick sees regulatory acceptance starting to translate into practice, aided by Certara's scientists being in direct dialogue with agencies. The NVIDIA partnership, teed up in Q1 and formalized now, is the visible sign of Certara's ambition to become the "accountability layer" for frontier models in regulated settings. “to my knowledge, it's the first major kind of technology partnership, and there are several other discussions as well.” — Jon Resnick, Chief Executive Officer · 2026-08-04 The aim is to let customers use cases ride atop NVIDIA's BioNeMo agent toolkit — echoing the May call where Resnick described the next-gen AI platform as already "in active discussion": “we're extremely excited about what's ahead of us there... it's going to create unique business models for us as we move forward.” — Jon Resnick, Chief Executive Officer · 2026-05-11 The optimism on the market itself has been consistent since February: “our view on the market is that it is strengthening, I think, consistent with what others are reporting.” — Jon Resnick, Chief Executive Officer · 2026-02-26 The scoreboard, however, remains mixed. Full-year guidance is unchanged at 0–4% revenue growth, but adjusted-R&D intensity keeps climbing — a deliberate bet on the platform — while net cash has swung to -$145M even after completing $100M of buybacks (a new $50M authorization signals confidence). Total Revenue tells the real story: a business still at zero growth. Certara is wagering its re-rating on execution discipline after a multi-year stretch of under-delivering on a strong franchise. The 52% 90-day rally says investors are buying the turn; the fundamentals still show services in re-adjustment, a margin guide that depends on realizing savings, and a pivot that has yet to show up in the income statement. The next two quarters will determine whether the leading indicators — pipeline creation and software ARR accumulation — convert into durable revenue.

The Verdict

This is a name-in-motion narrative: a strategic pivot (divestiture, RIF, new CCO, NVIDIA) layered on a +52% price rally, but with the financial proof still pending. The story is company-unique rather than sector boilerplate, and the evidence—stranded costs, precise pipeline numbers, regulatory milestones—is strong. The real question is whether the "execution gap" closes before investors lose patience.